New test could prevent unneeded prostate cancer treatment

A new test from Genomic Health, the Oncotype DX Prostate Cancer Test, could reduce the number of men who undergo treatment for low-risk prostate cancer that would be better left untreated. The test rates the aggressiveness of a prostate biopsy based on an analysis of 17 genes and is more accurate than currently available tests, the developers say.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX